TAE Life Sciences forges collaboration with Ohio State to innovate cancer treatments

In a significant development in precision oncology, TAE Life Sciences announced a partnership with The Ohio State University Comprehensive Cancer Center on May 3, 2025. The collaboration aims to advance the development of novel boron-based drug compounds as a crucial aspect of Boron Neutron Capture Therapy (BNCT). This partnership stands out as the first U.S.-based academic-industry alliance focused specifically on enhancing BNCT drug innovation and translational research. Both organizations will work on optimizing boron delivery agents to fully exploit BNCT's potential, which is known for offering highly selective, non-toxic cancer therapies. Dr. Arnab Chakravarti, Chair of Radiation Oncology at Ohio State, highlighted the unique opportunity BNCT presents in treating resistant cancers while preserving healthy tissue. He expressed confidence that the collaboration with TAE Life Sciences will accelerate research efforts on a global scale. The initial phase will involve preclinical evaluation of proprietary boron-10 drugs in both cellular and animal models, utilizing Ohio State's neutron source specifically optimized for BNCT research. This collaborative effort signifies a strategic advancement in the precision medicine sphere. Robert Hill, CEO of TAE Life Sciences, underscored the importance of this partnership, attributing it as a major leap for the future of BNCT. He acknowledged Dr. Chakravarti's team as vital in not only developing the science surrounding novel boron compounds but also for working towards regulatory approval for these new therapies. This collaboration marks a significant milestone towards establishing the United States as a leader in advanced cancer drug development and innovative precision medicine strategies. Clinical evidence from international studies supports BNCT's capability to provide durable responses in patients with previously untreatable cancers. Overall, this collaboration represents a dynamic force for innovation in the treatment of cancer, redefining how malignancies could be approached. It highlights a commitment to bridging the gap between academic research and industry applications, propelling forward scientific advancements and potential solutions for patients in need of novel therapeutic options. The focus on bolstering the U.S. position worldwide in drug development reflects a proactive approach to cancer care and research, reinforcing the vision of a cancer-free world.